Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
02 02 2022
Historique:
received: 13 01 2022
revised: 30 01 2022
accepted: 31 01 2022
entrez: 26 2 2022
pubmed: 27 2 2022
medline: 9 3 2022
Statut: epublish

Résumé

To investigate the dynamic association among binding and functional antibodies in health-care-workers receiving two doses of BNT162b2 mRNA COVID-19-vaccine, SARS-CoV-2 anti-RBD IgG, anti-Trimeric-S IgG, and neutralizing antibodies (Nabs) were measured in serum samples collected at 2 weeks, 3 months, and 6 months from full vaccination. Despite the high correlation, results for anti-RBD and anti-Trimeric S IgG were numerically different even after recalculation to BAU/mL following WHO standards indications. Moreover, after a peak response at 2 weeks, anti-RBD IgG levels showed a 4.5 and 13 fold decrease at 3 and 6 months, respectively, while the anti-Trimeric S IgG presented a less pronounced decay of 2.8 and 4.7 fold. Further different dynamics were observed for Nabs titers, resulting comparable at 3 and 6 months from vaccination. We also demonstrated that at NAbs titers ≥40, the area under the receiver operating characteristic curve and the optimal cutoff point decreased with time from vaccination for both anti-RBD and anti-Trimeric S IgG. The mutating relation among the anti-RBD IgG, anti-Trimeric S IgG, and neutralizing antibodies are indicative of antibody maturation upon vaccination. The lack of standardized laboratory procedures is one factor interfering with the definition of a correlate of protection from COVID-19.

Identifiants

pubmed: 35215903
pii: v14020312
doi: 10.3390/v14020312
pmc: PMC8878369
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Immunoglobulin G 0
BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministero della Salute
ID : Ricerca Corrente, Linea 1
Organisme : Ministero della Salute
ID : Ricerca Finalizzata COVID-2020-12371817
Organisme : European Union's Horizon 2020 research and innovation programme
ID : 871029-EVA- GLOBAL

Références

Lancet Microbe. 2021 Oct 26;:
pubmed: 34723229
Microbiol Spectr. 2021 Sep 3;9(1):e0024721
pubmed: 34190591
Front Physiol. 2021 Jan 12;11:571416
pubmed: 33510644
Pathogens. 2021 May 07;10(5):
pubmed: 34066983
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Lancet. 2021 Apr 10;397(10282):1347-1348
pubmed: 33770519
Natl Sci Rev. 2021 Mar 27;8(8):nwab053
pubmed: 34676098
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Science. 2022 Feb 11;375(6581):678-680
pubmed: 35040667
Vaccines (Basel). 2021 Jun 18;9(6):
pubmed: 34207300
Viruses. 2021 Apr 10;13(4):
pubmed: 33920222
Lancet. 2021 Apr 3;397(10281):1263-1264
pubmed: 33765410
Vaccines (Basel). 2021 Mar 10;9(3):
pubmed: 33801831
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
J Clin Virol. 2021 Nov;144:104986
pubmed: 34563862
Clin Infect Dis. 2008 Aug 1;47(3):401-9
pubmed: 18558875
Nat Med. 2021 Jul;27(7):1147-1148
pubmed: 34239135
Nat Med. 2022 Jan 20;:
pubmed: 35051990
Clin Chem Lab Med. 2021 Sep 08;59(12):2010-2018
pubmed: 34492749
Science. 2022 Jan 7;375(6576):43-50
pubmed: 34812653
Clin Chem Lab Med. 2021 Nov 23;60(2):e29-e31
pubmed: 34816677
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
Mayo Clin Proc. 2020 Oct;95(10):2189-2203
pubmed: 33012349
Front Immunol. 2020 Aug 07;11:1949
pubmed: 32849654
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
EBioMedicine. 2021 Nov;73:103677
pubmed: 34742128
Vaccines (Basel). 2021 Jun 01;9(6):
pubmed: 34205932
Science. 2021 Sep 17;373(6561):1372-1377
pubmed: 34385356
Clin Chim Acta. 2021 Nov;522:144-151
pubmed: 34425105

Auteurs

Giulia Matusali (G)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Giuseppe Sberna (G)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Silvia Meschi (S)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Giulia Gramigna (G)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Francesca Colavita (F)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Daniele Lapa (D)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Massimo Francalancia (M)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Aurora Bettini (A)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Maria R Capobianchi (MR)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Vincenzo Puro (V)

Risk Management Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Concetta Castilletti (C)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Francesco Vaia (F)

General Direction, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Licia Bordi (L)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH